Skip to main content

9 Result(s)

within R Lacchini Remove this filter Biomedicine Remove this filter

and

  1. No Access

    Article

    Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil

    Arginase 1 (ARG1) and arginase 2 (ARG2) compete with nitric oxide synthases for the substrate l-arginine. Here we aim to assess whether arginase 1 and 2 plasma levels, plasma arginase activity or genetic factors ...

    R Lacchini, J J Muniz, Y T D A Nobre, A J Cologna… in The Pharmacogenomics Journal (2018)

  2. No Access

    Article

    Gene–gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy

    Nicotinamide phosphorybosil transferase (NAMPT) polymorphisms affect visfatin/NAMPT levels and may affect the responsiveness to therapy in hypertensive disorders of pregnancy. We examined whether NAMPT polymorphi...

    M R Luizon, A C T Palei, V A Belo, L M Amaral, R Lacchini… in The Pharmacogenomics Journal (2017)

  3. No Access

    Article

    In reply to: Enalapril and the VEGFA gene: personalized medicine in hypertension therapy

    G. H. Oliveira-Paula, R. Lacchini… in European Journal of Clinical Pharmacology (2016)

  4. No Access

    Article

    Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril

    Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that affects blood pressure by promoting vasodilation mediated by nitric oxide. Angiotensin-converting enzyme inhibitors (ACEi) up-regula...

    G. H. Oliveira-Paula, R. Lacchini, V. Fontana… in European Journal of Clinical Pharmacology (2015)

  5. No Access

    Article

    Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy

    Tissue inhibitor of metalloproteinase (TIMP)-1 is a major endogenous inhibitor of matrix metalloproteinase (MMP)-9, which may affect the responsiveness to therapy in hypertensive disorders of pregnancy. We examin...

    M R Luizon, A C T Palei, V C Sandrim, L M Amaral… in The Pharmacogenomics Journal (2014)

  6. No Access

    Article

    VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction

    Vascular endothelial growth factor (VEGF) is a cytokine involved in angiogenesis and is closely related to the nitric oxide–cyclic guanosine monophosphate pathway, a target for sildenafil. We investigated for ...

    R Lacchini, J J Muniz, Y T D A Nobre, A J Cologna… in The Pharmacogenomics Journal (2013)

  7. No Access

    Article

    Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction

    Erectile dysfunction (ED) is usually treated with sildenafil. Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information ab...

    J J Muniz, R Lacchini, T O Rinaldi, Y T D A Nobre… in The Pharmacogenomics Journal (2013)

  8. No Access

    Article

    eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril

    The antihypertensive effect of angiotensin-converting enzyme inhibitors (ACEi) is attributed partially to increased nitric oxide bioavailability. It is possible that functional polymorphisms in endothelial nit...

    P. S. Silva, V. Fontana, M. R. Luizon… in European Journal of Clinical Pharmacology (2013)

  9. No Access

    Article

    Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy

    Abnormal matrix metalloproteinase (MMP)-9 levels may have a role in hypertensive disorders of pregnancy. We examined whether MMP-9 genetic polymorphisms (g.−1562C>T and g.−90(CA)13−25) modify plasma MMP-9 and tis...

    A C T Palei, V C Sandrim, L M Amaral, J S R Machado… in The Pharmacogenomics Journal (2012)